<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00137</title>
	</head>
	<body>
		<main>
			<p><!-- PJG FTAG 4717 -->  <!-- PJG STAG 4717 -->  <!-- PJG ITAG l=01 g=1 f=1 --> Friday <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=02 g=1 f=1 --> August 5, 1994 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=1 --> Part IV <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Department of Health and Human Services <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> National Institutes of Health <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> Recombinant DNA Research: Actions Under the Guidelines; Notice <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG -->  <!-- PJG FTAG 4701 -->  <!-- PJG STAG 4701 -->  <!-- PJG ITAG l=90 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=1 --> &blank;/&blank;Vol. 59, No. 150&blank;/&blank;Friday, August 5, 1994&blank;/&blank;Notices  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES </USDEPT>  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Recombinant DNA Research: Actions Under the Guidelines  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, PHS, DHHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice of Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  This notice sets forth three actions to be taken by the Director, National Institutes of Health (NIH), under the NIH Guidelines for Research Involving Recombinant DNA Molecules ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> , July 5, 1994, Part IV). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </SUMMARY> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Additional information can be obtained from Dr. Nelson A. Wivel, Director, Office of Recombinant DNA Activities (ORDA), Office of Science Policy and Technology Transfer, National Institutes of Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Today three actions are being promulgated under the NIH Guidelines for Research Involving Recombinant DNA Molecules. These three proposed actions were published for comment in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of May 11, 1994 (59 FR 24618), and reviewed and recommended for approval by the NIH Recombinant DNA Advisory Committee (RAC) at its meeting on June 9&hyph;10, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> I. Background Information and Decisions on Actions Under the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=4 --> NIH Guidelines  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> A. Amendment to Appendix M&hyph;I&hyph;D of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=3 --> NIH Guidelines Regarding Informed  <!-- PJG 0012 frnewline --> Consent for Human Gene Transfer Protocols  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> During the December 2&hyph;3, 1993, Recombinant DNA Advisory Committee  <!-- PJG 0012 frnewline --> meeting, Dr. Gary Ellis, Director of the Office for Protection from Research  <!-- PJG 0012 frnewline --> Risks (OPRR), NIH, Bethesda, Maryland, responded to the written comments  <!-- PJG 0012 frnewline --> submitted by Dr. Zallen, Chair of the Working Group on Informed Consent  <!-- PJG 0012 frnewline --> Issues. Dr. Ellis noted the Recombinant DNA Advisory Committee's concern  <!-- PJG 0012 frnewline --> regarding specific issues that should be addressed in human gene transfer  <!-- PJG 0012 frnewline --> protocol Informed Consent documents, i.e., request for autopsy,  <!-- PJG 0012 frnewline --> recommendations for male/female contraception, separate Informed Consent  <!-- PJG 0012 frnewline --> documents when the gene therapy aspects of the protocols are independent of an  <!-- PJG 0012 frnewline --> ongoing clinical protocol, commitment to long-term patient follow-up, and  <!-- PJG 0012 frnewline --> financial responsibility of the institution for all research-related costs. During his  <!-- PJG 0012 frnewline --> presentation, Dr. Ellis provided the Recombinant DNA Advisory Committee  <!-- PJG 0012 frnewline --> with background information regarding the roles of both OPRR and local  <!-- PJG 0012 frnewline --> Institutional Review Boards (IRB) in the review of research proposals involving  <!-- PJG 0012 frnewline --> human subjects. Dr. Ellis recommended that the Recombinant DNA Advisory  <!-- PJG 0012 frnewline --> Committee draft a letter outlining its specific recommendations to OPRR for  <!-- PJG 0012 frnewline --> distribution and consideration by the local IRBs.  <!-- PJG 0012 frnewline --> In a memorandum dated December 23, 1993, Dr. Ellis further clarified the  <!-- PJG 0012 frnewline --> avenues that should be pursued by the Recombinant DNA Advisory Committee  <!-- PJG 0012 frnewline --> with regard to translating its concern about the ``quality and content of informed  <!-- PJG 0012 frnewline --> consent documents into constructive changes in the informed consent process,''  <!-- PJG 0012 frnewline --> specifically in relation to human gene transfer. Dr. Ellis recommended that the  <!-- PJG 0012 frnewline --> NIH Guidelines should be amended to introduce consistency in Informed  <!-- PJG 0012 frnewline --> Consent document language.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG -->  <!-- PJG /FTAG --></p>
		</main>
</body></html>
            